Cargando…

Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses

Glioblastoma multiforme (GBM) is the most common adult primary brain malignancy, with dismal survival rates of ~14.6 months. The current standard-of-care consists of surgical resection and chemoradiotherapy, however the treatment response is limited by factors such as tumour heterogeneity, treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moran, Jennifer, Mylod, Eimear, Kane, Laura E., Marion, Caroline, Keenan, Emily, Mekhaeil, Marianna, Lysaght, Joanne, Dev, Kumlesh K., O’Sullivan, Jacintha, Conroy, Melissa J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959685/ https://www.ncbi.nlm.nih.gov/pubmed/36839682 http://dx.doi.org/10.3390/pharmaceutics15020360

Ejemplares similares

Olaparib Attenuates Demyelination and Neuroinflammation in an Organotypic Slice Culture Model of Metachromatic Leukodystrophy
por: Mekhaeil, Marianna, et al.
Publicado: (2023)

Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases
por: Mekhaeil, Marianna, et al.
Publicado: (2022)

The Omentum in Obesity-Associated Cancer: A Hindrance to Effective Natural Killer Cell Migration towards Tumour Which Can Be Overcome by CX3CR1 Antagonism
por: Mylod, Eimear, et al.
Publicado: (2021)

Investigating the susceptibility of treatment-resistant oesophageal tumours to natural killer cell-mediated responses
por: Mylod, Eimear, et al.
Publicado: (2022)

Glioblastoma Multiforme Stem Cells
por: Dimov, Irena, et al.
Publicado: (2011)

The chemokine fractalkine (CX3CL1) attenuates H(2)O(2)-induced demyelination in cerebellar slices
por: O’Sullivan, Sinead A., et al.
Publicado: (2017)

Glioblastoma Multiforme
por: Sheehan, Jonas M., et al.
Publicado: (2012)

Cancer Stem Cells in Glioblastoma Multiforme
por: Bradshaw, Amy, et al.
Publicado: (2016)

Cell-based immunotherapy of glioblastoma multiforme
por: Bryukhovetskiy, Igor
Publicado: (2022)

Simultaneous impact of atorvastatin and mesenchymal stem cells for glioblastoma multiform suppression in rat glioblastoma multiform model
por: Goodarzi, Arash, et al.
Publicado: (2020)

The Impact of Esophageal Oncological Surgery on Perioperative Immune Function; Implications for Adjuvant Immune Checkpoint Inhibition
por: Donlon, Noel E., et al.
Publicado: (2022)

Boosting Natural Killer Cell Therapies in Glioblastoma Multiforme Using Supramolecular Cationic Inhibitors of Heat Shock Protein 90
por: Saha, Tanmoy, et al.
Publicado: (2021)

Cerebellar giant cell glioblastoma multiforme in an adult
por: Mishra, Sudhansu Sekhar, et al.
Publicado: (2014)

Cancer Stem Cell Hierarchy in Glioblastoma Multiforme
por: Bradshaw, Amy, et al.
Publicado: (2016)

Glioblastoma multiforme – an overview
por: Urbańska, Kaja, et al.
Publicado: (2014)

Incidentalomas to glioblastoma multiforme
por: Sachdev, Bobby, et al.
Publicado: (2014)

Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells
por: Davern, Maria, et al.
Publicado: (2023)

VRK1 Depletion Facilitates the Synthetic Lethality of Temozolomide and Olaparib in Glioblastoma Cells
por: Navarro-Carrasco, Elena, et al.
Publicado: (2021)

The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures
por: O’Sullivan, Catherine, et al.
Publicado: (2016)

Honokiol-induced apoptosis and autophagy in glioblastoma multiforme cells
por: CHANG, KEN-HU, et al.
Publicado: (2013)

Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme
por: Yang, Liu, et al.
Publicado: (2015)

Neural Stem Cell Carriers for the Treatment of Glioblastoma Multiforme
por: Miska, Jason, et al.
Publicado: (2015)

Cellular and Molecular Comparison of Glioblastoma Multiform Cell Lines
por: Demircan, Turan, et al.
Publicado: (2021)

Fractalkine shedding is mediated by p38 and the ADAM10 protease under pro-inflammatory conditions in human astrocytes
por: O’Sullivan, Sinead A., et al.
Publicado: (2016)

Tectal plate glioblastoma multiforme
por: Nemer, Michael D., et al.
Publicado: (2011)

Bilateral cystic glioblastoma multiforme
por: Kumar, Sushil, et al.
Publicado: (2013)

Atypical Presentation of Glioblastoma Multiforme
por: Al-Janabi, Wissam, et al.
Publicado: (2018)

Nanotechnology for Treatment of Glioblastoma Multiforme
por: Michael, Justin S., et al.
Publicado: (2018)

The complement system in glioblastoma multiforme
por: Bouwens van der Vlis, T. A. M., et al.
Publicado: (2018)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Survival Analysis of Glioblastoma Multiforme
por: Witthayanuwat, Supapan, et al.
Publicado: (2018)

Advances in Immunotherapy for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2017)

Targeted Nanotechnology in Glioblastoma Multiforme
por: Glaser, Talita, et al.
Publicado: (2017)

Prion Protein in Glioblastoma Multiforme
por: Ryskalin, Larisa, et al.
Publicado: (2019)

Current Immunotherapies for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2021)

Glioblastoma Multiforme Masquerading as Stroke
por: Remley, William, et al.
Publicado: (2021)

Advances in immunotherapy for glioblastoma multiforme
por: Mahmoud, Ahmad Bakur, et al.
Publicado: (2022)

Immune phenotypes predict survival in patients with glioblastoma multiforme
por: Mostafa, Haouraa, et al.
Publicado: (2016)

Nestin expression in the cell lines derived from glioblastoma multiforme
por: Veselska, Renata, et al.
Publicado: (2006)

β-Catenin Signalling in Glioblastoma Multiforme and Glioma-Initiating Cells
por: Nager, Mireia, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_tqpuvj1bomtsclad8vd6en135j